These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1585 related articles for article (PubMed ID: 12641352)
1. Low-dose adjuvant interferon for stage III malignant melanoma. Inman JL; Russell GB; Savage P; Levine EA Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352 [TBL] [Abstract][Full Text] [Related]
2. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A; Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144 [TBL] [Abstract][Full Text] [Related]
3. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H; Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809 [TBL] [Abstract][Full Text] [Related]
4. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184 [TBL] [Abstract][Full Text] [Related]
6. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D; Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216 [TBL] [Abstract][Full Text] [Related]
8. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998 [TBL] [Abstract][Full Text] [Related]
9. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813 [TBL] [Abstract][Full Text] [Related]
10. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637 [TBL] [Abstract][Full Text] [Related]
12. Recent advances in the care of the patient with malignant melanoma. Reintgen D; Balch CM; Kirkwood J; Ross M Ann Surg; 1997 Jan; 225(1):1-14. PubMed ID: 8998115 [TBL] [Abstract][Full Text] [Related]
13. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. Cole BF; Gelber RD; Kirkwood JM; Goldhirsch A; Barylak E; Borden E J Clin Oncol; 1996 Oct; 14(10):2666-73. PubMed ID: 8874325 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Anaya DA; Xing Y; Feng L; Huang X; Camacho LH; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Cormier JN Cancer; 2008 May; 112(9):2030-7. PubMed ID: 18320602 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy in melanoma. Mohr P; Weichenthal M; Hauschild A Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]